JPMorgan Chase & Co. Lowers U.S. Physical Therapy (NYSE:USPH) Price Target to $99.00

U.S. Physical Therapy (NYSE:USPH) had its price target cut by JPMorgan Chase & Co. from $108.00 to $99.00 in a research report sent to investors on Friday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts also recently issued reports on USPH. CJS Securities raised shares of U.S. Physical Therapy from a market perform rating to an outperform rating in a research report on Tuesday, September 19th. TheStreet lowered U.S. Physical Therapy from a b- rating to a c+ rating in a research report on Wednesday, October 4th. Barrington Research decreased their price objective on U.S. Physical Therapy from $124.00 to $111.00 and set an outperform rating for the company in a report on Thursday, November 9th. Finally, StockNews.com upgraded shares of U.S. Physical Therapy from a sell rating to a hold rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, U.S. Physical Therapy currently has an average rating of Moderate Buy and a consensus price target of $116.00.

U.S. Physical Therapy Stock Up 1.6 %

Shares of U.S. Physical Therapy stock opened at $86.05 on Friday. The company’s 50 day moving average price is $88.78 and its 200-day moving average price is $102.94. U.S. Physical Therapy has a 52-week low of $78.08 and a 52-week high of $124.11. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.77 and a current ratio of 2.77. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 50.03, a P/E/G ratio of 5.15 and a beta of 1.38.

U.S. Physical Therapy (NYSE:USPH) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The firm had revenue of $150.00 million during the quarter, compared to the consensus estimate of $148.85 million. U.S. Physical Therapy had a net margin of 5.11% and a return on equity of 9.03%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.58 earnings per share. Equities research analysts forecast that U.S. Physical Therapy will post 2.54 EPS for the current year.

U.S. Physical Therapy Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Thursday, November 16th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Wednesday, November 15th. This represents a $1.72 annualized dividend and a dividend yield of 2.00%. U.S. Physical Therapy’s dividend payout ratio is presently 100.00%.

Insider Buying and Selling

In related news, COO Graham D. Reeve sold 1,500 shares of U.S. Physical Therapy stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $87.39, for a total value of $131,085.00. Following the completion of the sale, the chief operating officer now directly owns 7,801 shares in the company, valued at approximately $681,729.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Kathleen A. Gilmartin purchased 1,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $82.34 per share, for a total transaction of $82,340.00. Following the purchase, the director now directly owns 15,480 shares in the company, valued at approximately $1,274,623.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Graham D. Reeve sold 1,500 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $87.39, for a total transaction of $131,085.00. Following the completion of the transaction, the chief operating officer now owns 7,801 shares in the company, valued at approximately $681,729.39. The disclosure for this sale can be found here. 1.80% of the stock is owned by company insiders.

Institutional Trading of U.S. Physical Therapy

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund grew its position in shares of U.S. Physical Therapy by 10.5% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,630 shares of the company’s stock valued at $562,000 after acquiring an additional 440 shares during the period. Royce & Associates LP raised its stake in shares of U.S. Physical Therapy by 46.8% in the second quarter. Royce & Associates LP now owns 62,300 shares of the company’s stock worth $7,563,000 after buying an additional 19,859 shares during the period. Texas Permanent School Fund Corp lifted its position in shares of U.S. Physical Therapy by 11.2% during the 2nd quarter. Texas Permanent School Fund Corp now owns 12,969 shares of the company’s stock valued at $1,574,000 after buying an additional 1,309 shares in the last quarter. Commerce Bank purchased a new stake in U.S. Physical Therapy in the 2nd quarter worth approximately $329,000. Finally, Bank of Montreal Can purchased a new stake in U.S. Physical Therapy in the 2nd quarter worth approximately $416,000.

About U.S. Physical Therapy

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.